CLINICAL RESEARCH: HEART FAILURE
Evaluation and Long-Term Prognosis of New-Onset, Transient, and Persistent Anemia in Ambulatory Patients With Chronic Heart Failure
W.H. Wilson Tang, MD, FACC*,1,*,
Wilson Tong, MSc*,
Anil Jain, MD , ,
Gary S. Francis, MD, FACC*,1,
C. Martin Harris, MD, MBA and
James B. Young, MD, FACC*,1
* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio
Information Technology Division, Cleveland Clinic, Cleveland, Ohio.
Manuscript received May 14, 2007;
revised manuscript received July 20, 2007,
accepted July 23, 2007.
* Reprint requests and correspondence: Dr. W. H. Wilson Tang, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195. (Email: tangw{at}ccf.org).
Objectives: This study sought to determine the characteristics and long-term prognosis of anemia in ambulatory patients with chronic heart failure.
Background: Anemia is prevalent in heart failure, and may portend poor outcomes.
Methods: We reviewed 6,159 consecutive outpatients with chronic stable heart failure at baseline, short-term (3-month) follow-up, and long-term (6-month) follow-up between 2001 and 2006. Clinical, demographic, laboratory, and echocardiographic data were reviewed from electronic medical records. Mortality rates were determined from 6-month follow-up to end of study period.
Results: Prevalence of anemia (hemoglobin [Hb] <12 g/dl for men, <11 g/dl for women) was 17.2% in our cohort. Diabetes, B-natriuretic peptide, left ventricular ejection fraction, and estimated glomerular filtration rate were independent predictors of baseline anemia. Documented evaluation of anemia was found in only 3% of all anemic patients, and better in internal medicine than in cardiology clinics. At 6-month follow-up, new-onset anemia developed in 16% of patients without prior anemia, whereas 43% patients with anemia at baseline had resolution of their hemoglobin levels. Higher total mortality rates were evident in patients with persistent anemia (58% vs. 31%, p < 0.0001) or with incident anemia (45% vs. 31%, p < 0.0001) compared with those with without anemia at 6 months.
Conclusions: These observations in a broad unselected outpatient cohort suggest that anemia in patients with heart failure is under-recognized and underevaluated. However, resolution of anemia was evident in up to 43% of patients who presented initially with anemia, and did not pose greater long-term risk for all-cause mortality. However, the presence of persistent anemia conferred poorest survival in patients with heart failure when compared with that of incident, resolved, or no anemia.
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | BNP = B-type natriuretic peptide | | eGFR = estimated glomerular filtration rate | | Hb = hemoglobin | | ICD-9 = International Classification of Diseases-Ninth Revision | | LVEF = left ventricular ejection fraction | | MCV = mean corpuscular volume |
|
Related Articles
-
Anemia in Heart Failure: Marker or Mediator of Adverse Prognosis?
- Wayne C. Levy
J. Am. Coll. Cardiol. 2008 51: 577-578.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 51: A29-A30.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Krikorian
Managing Anemia of Chronic Kidney Disease
American Journal of Lifestyle Medicine,
March 1, 2009;
3(2):
135 - 146.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kazory and E. A. Ross
Anemia: the point of convergence or divergence for kidney disease and heart failure?
J. Am. Coll. Cardiol.,
February 24, 2009;
53(8):
639 - 647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al.
Highlights of the Year in JACC 2008.
J. Am. Coll. Cardiol.,
January 27, 2009;
53(4):
373 - 398.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. V. Patel and J. M. Guralnik
Prognostic implications of anemia in older adults
Haematologica,
January 1, 2009;
94(1):
1 - 2.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
November 11, 2008;
52(20):
1671 - 1678.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer
Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis
J. Am. Coll. Cardiol.,
September 2, 2008;
52(10):
818 - 827.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Silverberg, D. Wexlerb, A. Iaina, and D. Schwartz
The role of correction of anaemia in patients with congestive heart failure: A short review
Eur J Heart Fail,
September 1, 2008;
10(9):
819 - 823.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. J. Sehnert, S. E. Daniels, M. Elashoff, J. A. Wingrove, C. R. Burrow, B. Horne, J. B. Muhlestein, M. Donahue, S. B. Liggett, J. L. Anderson, et al.
Lack of Association Between Adrenergic Receptor Genotypes and Survival in Heart Failure Patients Treated With Carvedilol or Metoprolol
J. Am. Coll. Cardiol.,
August 19, 2008;
52(8):
644 - 651.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. C. Levy
Anemia in heart failure: marker or mediator of adverse prognosis?
J. Am. Coll. Cardiol.,
February 5, 2008;
51(5):
577 - 578.
[Full Text]
[PDF]
|
 |
|
|